Literature DB >> 4618580

Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy) propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent beta-adrenergic blocking agent.

Y Yabuochi, D Kinoshita.   

Abstract

The beta-adrenergic blocking and hemodynamic properties of 5-(3-tert-butyl-amino-2-hydroxy) propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085) were investigated and compared with those of propranolol and pindolol on myocardial contractile force, heart rate and arterial blood pressure in pentobarbital anesthetized dogs. OPC-1085 showed almost the same beta-adrenergic blocking potency as pindolol, but was approximately 30 and 20 times stronger than propranolol against isoproterenol and cardiac nerve stimulation, respectively. Slight negative inotropic and chronotropic responses were observed with OPC-1085 in effective blocking doses from 1 to 10 mug/kg but were converted to positive ones in doses from 30 to 3000 mug/kg in non-reserpinized dogs. In reserpinized dogs, both OPC-1085 and pindolol induced only positive responses. These responses were more evident with OPC-1085.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4618580     DOI: 10.1254/jjp.24.853

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  10 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Effects of S-596 and carteolol, new beta-adrenergic blockers, and flurbiprofen on the human eye: a fluorophotometric study.

Authors:  M Araie; M Takase
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1985       Impact factor: 3.117

3.  Effects of the beta1-selective adrenergic antagonist betaxolol on electroretinography in the perfused cat eye.

Authors:  Yukitaka Uji; Manami Kuze; Hisashi Matubara; Motoaki Doi; Mikio Sasoh
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

4.  A controlled study of the antihypertensive effect of carteolol, a new beta-adrenergic receptor blocking drug, in combination with hydrochlorothiazide and amiloride.

Authors:  A Tarkiainen; K Saraste; T Seppälä; A Gordin; J Auvinen
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

Review 5.  Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

6.  Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension.

Authors:  T Baba; S Murabayashi; T Tomiyama; K Takebe
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Profile of beta-adrenoceptors in femoral, superior mesenteric and renal vascular beds of dogs.

Authors:  N Taira; Y Yabuuchi; S Yamashita
Journal:  Br J Pharmacol       Date:  1977-04       Impact factor: 8.739

8.  Concentration-effect and time-effect relationships of carteolol.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Chiba; T Suganuma; K Kushida
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Effects of carteolol on the electroretinogram in the perfused cat eye.

Authors:  N Miyamura; Y Uji
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

10.  Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination.

Authors:  Kenji Inoue; Hua Piao; Mayumi Iwasa; Kyoko Ishida; Goji Tomita
Journal:  Clin Ophthalmol       Date:  2020-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.